Abstract
Purpose The neurobiological heterogeneity present in schizophrenia remains poorly understood. This likely contributes to the limited success of existing treatments and the observed variability in treatment responses. Our objective was to employ magnetic resonance imaging (MRI) and machine learning (ML) algorithms to improve the classification of schizophrenia and its subtypes.
Method We utilized a public dataset provided by the UCLA Consortium for Neuropsychiatric Research, containing structural MRI and resting-state fMRI (rsfMRI) data. We integrated all individuals within the dataset diagnosed with schizophrenia (N=50); along with age- and gender-matched healthy individuals (N=50). We extracted volumetrics of 66 subcortical and thickness of 72 cortical regions. Additionally, we obtained four graph-based measures for 116 intracranial regions from rsfMRI data including degree, betweenness centrality, participation coefficient, and local efficiency. Employing conventional ML methods, we sought to distinguish the patients with schizophrenia from healthy individuals. Furthermore, we applied the methods for discriminating subtypes of schizophrenia. To streamline the feature set, various feature selection techniques were applied. Furthermore, a validation phase involved employing the model on a dataset domestically acquired using the same imaging assessments (N=13). Finally, we explored the correlation between neuroimaging features and behavioral assessments.
Finding The classification accuracy reached as high as 79% in distinguishing schizophrenia patients from healthy in the UCLA dataset. This result was achieved by the k-nearest neighbor algorithm, utilizing 12 brain neuroimaging features, selected by the feature selection method of Minimum Redundancy Maximum Relevance (MRMR). The model demonstrated high effectiveness (85% accuracy) in estimating the disease vs. control label for a new dataset acquired domestically. Using a linear SVM on 62 features obtained from MRMR, patients with schizophrenic subtypes were classified with an accuracy of 64%. The highest spearman correlation coefficient between the neuroimaging features and behavioral assessments was observed between degree of the postcentral gyrus and mean reaction time in the verbal capacity task (r = 0.49, p = 0.001).
Conclusion The findings of this study underscore the utility of MRI and ML algorithms in enhancing the diagnostic process for schizophrenia. Furthermore, these methods hold promise for detecting both brain-related abnormalities and cognitive impairments associated with this disorder.
Highlights
The neurobiological heterogeneity present in schizophrenia remains poorly understood.
This likely contributes to the limited success of existing treatments and the observed variability in treatment responses.
Magnetic resonance imaging (MRI) and machine learning (ML) algorithms can improve the classification of schizophrenia and its subtypes.
Structural and functional measures of MRI can discriminate Schizophrenia form healthy individuals with almost 80% accuracy.
Paranoid is the most distinguishable subtype of schizophrenia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Strategic Technologies Development of National Elite Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent according to the study protocol approved by the ethics committee of research, Iran University of Medical Sciences.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.